Ovarian cancer: risk factors, treatment and management
Author:
- 26 September 2013
- journal article
- review article
- Published by Mark Allen Group in British Journal of Nursing
- Vol. 22 (Sup17) , S23-S30
Abstract
Ovarian cancer is the fifth most common cancer affecting women in the UK today, with associated statistics illustrating a steadily increasing rate, particularly in women aged 65 and over ( Cancer Research UK, 2013 ). There are no recognised preventative measures and no effective screening tool. Although evidence suggests that the majority of women experience a variety of non-specific symptoms in the year before diagnosis, the disease it is not commonly recognised until an advanced stage, leading to increased mortality and morbidity. This highlights the need to raise awareness among health professionals and women as a whole, as early recognition undoubtedly improves ovarian cancer survival. Best clinical practice in the UK for the recognition and initial management of ovarian cancer is provided by the National Institute for Health and Care Excellence (NICE). Clinical guideline CG 122 ( NICE, 2011 ) and quality standard QS 18 ( NICE, 2012 ) use relevant clinical evidence to define high-quality care standards for ovarian cancer management. Accurate staging of ovarian cancer is essential to the provision of individualised care and management. However, there is currently no single test that provides a reliable indicator of ovarian malignancy. At present, risk-of-malignancy scores are calculated by serum cancer antigen 125 (CA 125) levels, ultrasound score and menopausal status. These are widely used to identify women who are at high risk and require referral to a specialised gynaecological oncology service. Women diagnosed with ovarian cancer require information and support. The clinical nurse specialist acts as a key worker, providing communication, support and holistic care throughout a woman's cancer journey. The value of this role cannot be underestimated. Surgery followed by platinum-based chemotherapy is the usual standard treatment pathway, although individualised assessment and management may deviate from it. Early disease may be successfully treated with surgery alone; advanced disease may require complex management and treatment. New treatments such as bevacizumab show promise of improving ovarian cancer outcomes.Keywords
This publication has 57 references indexed in Scilit:
- Sonographic predictors of ovarian malignancyJournal of Clinical Ultrasound, 2013
- Estimates of cancer incidence and mortality in Europe in 2008European Journal of Cancer, 2010
- Identifying symptoms of ovarian cancer: a qualitative and quantitative studyBJOG: An International Journal of Obstetrics & Gynaecology, 2008
- Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous CancerJournal of Clinical Oncology, 2007
- Ovarian cancer and hormone replacement therapy in the Million Women StudyThe Lancet, 2007
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerNew England Journal of Medicine, 2006
- Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-AnalysisJournal of Clinical Oncology, 2002
- A prognostic model for ovarian cancerBritish Journal of Cancer, 2001
- Prospective evaluation of three different models for the pre‐operative diagnosis of ovarian cancerBJOG: An International Journal of Obstetrics & Gynaecology, 2000
- EditorialInternational Journal of Gynecology & Obstetrics, 2000